AN ECONOMIC boost is on the way with the announcement that medtech company Aerogen is to create 725 new jobs in Galway and Shannon as part of a €300million expansion.
The Enterprise Ireland client announced details of a €300million transformational scaling and investment plan, which will result in the creation of 725 new jobs in Ireland over the next 10 years.
Aerogen is Ireland’s largest indigenous medtech company and Enterprise Ireland’s largest client company in the sector having established itself as a leader in acute care aerosol drug delivery.
The announcement was made in conjunction with Enterprise Ireland’s End of Year Results for 2024.
Deputy Peter Burke was on site in Galway to preside over the announcement.
Sign up for the weekly Limerick Post newsletter
“Aerogen’s announcement today is evidence of that Irish multinational ambition in action, and we are delighted to support them on their patient-focused mission,” he said.
With over 25 years of experience, 300 international patents and over 200 clinical papers, Aerogen technology has been used to treat over 25 million patients in emergency departments, adult and paediatric ICUs, general wards, and ambulance services in 75 countries worldwide.
Aerogen offers a drug delivery device for the treatment of critical respiratory illness and other non-respiratory illnesses and manufactures high performance, single-use, respiratory nebulisers.
The Aerogen Group is headquartered in Dangan, Galway, and has two manufacturing sites in Parkmore, Galway, and Shannon.
The implementation of the transformational scaling plan will enable Aerogen to create up to 725 highly skilled jobs in the West by 2035 increasing its global workforce to over 2,000 of which over 1,100 will be based in Ireland.
